Live tape
Top 8, mentions 7d29,939NVDA14,525 mentions▲ +0.04ANT4,149 mentions▲ +0.07GOOGL2,923 mentions▲ +0.04SPY2,246 mentions▲ +0.05QQQ1,802 mentions▲ +0.04SPCX1,745 mentions▲ +0.08AMD1,365 mentions▲ +0.06AAPL1,184 mentions▲ +0.04

Equity · Healthcare

RPRX

NASDAQ

Royalty Pharma (RPRX)

57.14 USD −0.86% vs prior close Oct 2, 2026
Royalty Pharma plc price graph
29 sessions
65.0 55.0 24 Aug 2 Oct

The line runs 61 USD on 24 August through 57.14 USD on 2 October, on a scale from 55.0 to 65.0. Days the market did not trade hold the previous close, flat.

Market cap
25.6B USD
P/E (TTM)
37.4
Revenue, year to Dec 2025
2.4B USD
EPS, diluted, year to Dec 2025
1.78 USD
52-week range
35 USD – 64 USD
Avg volume
200.5K

as of Oct 2, 2026

Have Royalty Pharma (RPRX) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Royalty Pharma insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 5 Nov 2025, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026

0buys
7sells
$32.57Mnet sold
7other filings
Have Royalty Pharma (RPRX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Nov 2026Coyne Terrance P.EVP & CFOSell24,5861.7M USD
17 Nov 2026Hite ChristopherEVP & Chairman, PartneringSell100,0006.8M USD
16 Nov 2026Coyne Terrance P.EVP & CFOSell232,53616.0M USD
16 Nov 2026Urist MarshallEVP, Research & InvestmentsSell25,0001.7M USD
05 Oct 2026Urist MarshallEVP, Research & InvestmentsSell4,126236K USD
28 Sep 2026Urist MarshallEVP, Research & InvestmentsSell4,126239K USD
22 Sep 2026Hite ChristopherEVP & Chairman, PartneringSell100,0005.9M USD
Sold7 open-market sales490,374$32.57M
7 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Royalty Pharma (RPRX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
06 Nov 2026Coyne Terrance P.EVP & CFOOther250,000
06 Nov 2026Urist MarshallEVP, Research & InvestmentsOther150,000
04 Nov 2026Coyne Terrance P.EVP & CFOAward7,122
04 Nov 2026Hite ChristopherEVP & Chairman, PartneringAward7,122
04 Nov 2026Legorreta Pablo G.CEO, Chairman of the BoardAward42,209
04 Nov 2026Urist MarshallEVP, Research & InvestmentsAward5,341
30 Sep 2026Bassler Bonnie LDirectorAward64237K USD

Which funds hold Royalty Pharma (RPRX)?

12 of the 45 institutional funds we track reported a Royalty Pharma position for the quarter ended 30 Sep 2026 — a combined 710.3M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Royalty Pharma (RPRX)?
FundPositionSharesValueShares q/q
AQR Capital ManagementHeld (±25%)3,709,286215.2M USD−13.8%
Two Sigma InvestmentsHeld (±25%)2,213,896129.2M USD−24.2%
Citadel AdvisorsHeld (±25%)1,471,04485.9M USD+8.6%
Point72 Asset ManagementAdded1,123,25665.6M USD+954.2%
Balyasny Asset ManagementNew position678,74139.6M USD
Marshall WaceTrimmed631,70036.9M USD−74.2%
Renaissance TechnologiesTrimmed591,10034.5M USD−69.5%
Tudor Investment CorpHeld (±25%)510,73629.8M USD−16.4%
Bridgewater AssociatesAdded474,52127.7M USD+116.0%
D. E. Shaw & Co.Held (±25%)413,89824.2M USD−21.2%

Showing the 10 largest of 12 reported positions. The figures above count all of them.

What has been filed or recorded for Royalty Pharma (RPRX)?

The filings we hold for Royalty Pharma, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 28 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Royalty Pharma (RPRX)?
And
28 Oct 2026Fails to deliverShares failed to deliver54 shares4K USD notional · <0.001% of shares out
26 Oct 2026Fails to deliverShares failed to deliver21,370 shares1.4M USD notional · 0.005% of shares out
09 Oct 2026Fails to deliverShares failed to deliver23,760 shares1.3M USD notional · 0.005% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 0.32 USDRevenue $690M
30 Sep 2026FinancialsTotal assets19.5B USDat period end
30 Sep 2026FinancialsTotal equity incl. minority interest9.8B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 0.04 USDRevenue $674M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.67 USDRevenue $631M
31 Dec 2025Annual reportFY 2025 reportedEPS 1.78 USDRevenue $2.38B
31 Dec 2025FinancialsRevenue2.4B USDfiscal year
31 Dec 2025FinancialsNet income770.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS1.78 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 0.66 USDRevenue $609M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.07 USDRevenue $579M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.55 USDRevenue $568M
31 Dec 2024Annual reportFY 2024 reportedEPS 1.91 USDRevenue $2.26B

What do people ask about Royalty Pharma (RPRX)?

From live data
What did Royalty Pharma shares close at?57.14

Royalty Pharma closed at 57.14 USD on 2 Oct 2026, down 0.86% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Royalty Pharma’s market cap?25.6B

Royalty Pharma is worth 25.6B USD by market value as of 2 Oct 2026, which is the share price times the shares on issue from its SEC filings.

What is Royalty Pharma’s P/E ratio?37.4

Royalty Pharma has a price-to-earnings ratio of 37.4, as of 2 Oct 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Royalty Pharma’s revenue?2.4B

Royalty Pharma reported revenue of 2.4B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Royalty Pharma insiders bought or sold shares recently?7 sales

In the 90 days to 22 Nov 2026, Royalty Pharma insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 5 Nov 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Royalty Pharma?12 of 45

12 of the 45 funds we track reported a Royalty Pharma position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Citadel Advisors. See Funds

When did Royalty Pharma last report earnings?0.32

Royalty Pharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.32 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words